Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

New England Journal of Medicine

Volumn 377, Issue 19, 2017, Pages 1824-1835

  Weber, Jeffrey ^a   Mandala, Mario ^b   Del Vecchio, Michele ^c   Gogas, Helen J ^h   Arance, Ana M ⁱ   Cowey, C Lance ^k   Dalle, Stéphane ^l   Schenker, Michael ^q   Chiarion Sileni, Vanna ^d   Marquez Rodas, Ivan ^j   Grob, Jean Jacques ^m   Butler, Marcus O ^r   Middleton, Mark R ^t   Maio, Michele ^e   Atkinson, Victoria ^v   Queirolo, Paola ^f   Gonzalez, Rene ^x   Kudchadkar, Ragini R ^y   Smylie, Michael ^s   Meyer, Nicolas ⁿ   Mortier, Laurent ^o   Atkins, Michael B ^z   Long, Georgina V ^w   Bhatia, Shailender ^aa   Lebbé, Celeste ^p   Rutkowski, Piotr ^ab   Yokota, Kenji ^ac   Yamazaki, Naoya ^ad   Kim, Tae M ^ae   De Pril, Veerle ^af   Sabater, Javier ^af   Qureshi, Anila ^af   Larkin, James ^u   Ascierto, Paolo A ^g   more..

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k TEXAS ONCOLOGY   (United States)

^l HOSPICES CIVILS DE LYON   (France)

^m AIX MARSEILLE UNIVERSITY   (France)

ⁿ TOULOUSE UNIVERSITY HOSPITAL   (France)

^o UNIV LILLE   (France)

^p SAINT LOUIS HOSPITAL   (France)

^q Oncology Center Sf Nectarie   (Romania)

^r UNIVERSITY OF TORONTO   (Canada)

^s CROSS CANCER INSTITUTE   (Canada)

^t UNIVERSITY OF OXFORD   (United Kingdom)

^u INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^v UNIVERSITY OF QUEENSLAND   (Australia)

^w UNIVERSITY OF SYDNEY   (Australia)

^x UNIVERSITY OF COLORADO   (United States)

^y EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^z GEORGETOWN UNIVERSITY   (United States)

^aa UNIVERSITY OF WASHINGTON   (United States)

^ab INSTITUTE OF ONCOLOGY   (Poland)

^ac NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ad NATIONAL CANCER CENTER HOSPITAL   (Japan)

^ae Seoul National University Hospital   (South Korea)

^af BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; INTENTION TO TREAT ANALYSIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE FREE SURVIVAL; SIDE EFFECT; ADOLESCENT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; QUALITY OF LIFE; SKIN TUMOR; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY OF LIFE; SKIN NEOPLASMS; YOUNG ADULT;

EID: 85033400433     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1709030     Document Type: Article

References (20)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
3. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
4. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-84.
5. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of highrisk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522-30.
6. Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375: 1845-55.
7. Coens C, Suciu S, Chiarion-Sileni V, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol 2017; 18: 393-403.
8. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
9. Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011; 117: 4740-06.
10. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
11. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
12. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015; 5: 915-9.
13. Tarhini AA, Zahoor H, Yearley JH, et al. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med 2015; 13: 319.
14. Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected highrisk metastatic melanoma. Clin Cancer Res 2015; 21: 712-20.
15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
16. EuroQol Group. EuroQol - a new facility for the measurement of healthrelated quality of life. Health Policy 1990; 16: 199-208.
17. Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 2017; 3: 1051-8.
18. Sunshine JC, Nguyen PL, Kaunitz GJ, et al. PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Cancer Res 2017; 23: 4938-44.
19. Tarhini AA, Lee SJ, Hodi FS, et al. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus highdose interferon alfa-2b for resected highrisk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms. J Clin Oncol 2017; 35: Suppl: 9500. abstract.
20. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017; 376: 2211-22.